JAK2 and essential thrombocythemia: The risk of thrombosis is higher in JAK2 mutated PMF compared to CALR mutated PMF, despite the fact that calreticulin mutated patients display higher platelet counts, both in essential thrombocythemia and in PMF [28,31].